reports
- James Carthew
- Matthew Read
Oakley Capital Investments – Getting down to business
In spite of what seems like an uncertain macroeconomic environment, Oakley Capital Investments’ (OCI) underlying portfolio continued to generate earnings growth in 2023 (average 14% EBITDA growth), which in turn helped drive 4% NAV growth. In addition, OCI achieved an 18% total shareholder return (TSR) during the period, extending the long run of performance delivered by the company (five-year TSR CAGR of 24%). The same macro uncertainty may also be creating opportunities. OCI’s investment mana...
Oakley Capital Investments Limited: 2 directors
Two Directors at Oakley Capital Investments Limited bought 400,000 shares at 449p. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- Andrew Courtney
- James Carthew
Oakley Capital Investments
Despite broader economic challenges, Oakley Capital Investments (OCI) continues to deliver market beating shareholder returns. A focus on cash-generative companies with recurring revenues and asset-light business models means the portfolio appears to be well insulated as financial conditions have tightened, which the managers note is highlighted by double digit earnings growth over the last financial year. The staggered nature of its investments appears to provide a consistent stream of realisat...
- Andrew Courtney
- James Carthew
Oakley Capital Investments
Despite broader economic challenges, Oakley Capital Investments (OCI) continues to deliver outstanding, market beating shareholder returns. Its focus on cash-generative companies with recurring revenues and asset-light business models means the portfolio remains well insulated as financial conditions have tightened, highlighted by double digit earnings growth over the last financial year. The staggered nature of its investments has provided a consistent stream of realisations (at an average prem...
- Shonil Chande
LIBERUM: Alternatives Daily
Oakley Capital Investments - CMD highlights wider portfolio opportunitiesBioPharma Credit - $137.5m loan at 3M SOFR + 7.5%3i Group - Strong results for 2023 and another 9.2% increase in dividendsBluefield Solar Income Fund - Power curve update and construction behind 2.3% NAV decline in Q1
- Shonil Chande
- Shonil Chande
LIBERUM: Alternatives Daily: HEIT | OCI | AEWU | AERI | RHM
Harmony Energy Income Trust - Note: Best placed for a shifting marketOakley Capital Investments - Solid Q1 with c.1.1% impact from organic growthAEW UK REIT - Improved dividend cover in Q1Aquila European Renewables - 12.9% NAV TR in FY22Round Hill Music Royalty - Attractive value
- Liberum Research Team
LIBERUM: Analyst Best Ideas - Most & Least Preferred Ideas from Liberu...
Liberum's research coverage encompasses more than 300 stocks across 12 pillars. Each quarter we ask our sector teams to list their most and least preferred stocks on a six to 12-month time horizon. Stock selection is largely limited to those names listed in the FTSE 350 and STOXX 600, eliminating less liquid names, and is driven by analysts’ preferences, rather than total shareholder return.
J2B EXPERIAN PLC
AHT ASHTEAD GROUP PLC
KLR KELLER GROUP PLC
MGAM MORGAN ADVANCED MATERIALS
7CT CENTAMIN PLC
HVO HVIVO
ABDP AB DYNAMICS
CARD CARD FACTORY
DOM DOMINO'S PIZZA GROUP PLC
OCI OAKLEY CAPITAL INVESTMENTS
RMG ROYAL MAIL PLC
CTEC CONVATEC GROUP PLC
IAG IAG
SSPG SSP GROUP PLC
TRN TRAINLINE PLC
TRR TRIDENT ROYALTIES
- Brian Moretta
- Mark Thomas
- Martin Hall
- Riccardo Bindi
Hardman & Co Monthly: April 2023
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
- James Carthew
- Matthew Read
Oakley Capital Investments – The best-performing UK-listed private equ...
Oakley Capital Investments (OCI) invests in private equity funds managed by Oakley Capital Limited (Oakley). OCI is, as we show on page 21, the best-performing fund in its peer group over five years. As evidenced by its latest full-year results, this has been achieved in spite of what might be described as a difficult macro backdrop. OCI’s manager believes that this can be attributed to three core factors: the expertise that it has built in a focused group of sectors (technology, consumer, educ...
- James Carthew
- Matthew Read
Oakley Capital Investments – The best-performing UK-listed private equ...
Oakley Capital Investments (OCI) invests in private equity funds managed by Oakley Capital Limited (Oakley). OCI is, as we show on page 21, the best-performing fund in its peer group over five years. As evidenced by its latest full-year results, this has been achieved in spite of a difficult macro backdrop. OCI believes that this can be attributed to three core factors: the expertise that it has built in a focused group of sectors (technology, consumer, education) over 20 years of investing; a ...
Hardman & Co Q&A on Oakley Capital Investments (OCI): 2022 Results: EB...
Hardman & Co Research Hardman & Co Q&A on Oakley Capital Investments (OCI): 2022 Results: EBITDA Growth Drives NAV Appreciation 31-March-2023 / 08:00 GMT/BST The issuer is solely responsible for the content of this announcement. Analyst interview | Investment Companies Q&A Oakley Capital Investments (OCI) | 2022 Results: EBITDA Growth Drives NAV Appreciation Oakley Capital Investments is the topic of conversation when Mark Thomas joins DirectorsTalk Interviews. Mark gives us an overview of his report entitled ‘’, explains how the investee companies delivered 22% EBITDA...
Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBIT...
The January trading statement announced NAV (662p per share), total NAV return (24%), NAV growth driven by EBITDA growth (65%), modest multiple expansion (35%), investments (£271m), realisations (£244m), available finance, including cash (£210m), and commitments (£929m). The detailed results announcement highlighted i) 2022 exits, on average, 70% above carrying value, ii) 22% investee company average earnings growth, iii) weighted average EV/EBITDA of 15.9x, below listed market levels, iii) a PE...
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: N...
Hardman & Co Research Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBITDA growth 15-March-2023 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBITDA growth The announced NAV (662p per share), total NAV return (24%), NAV growth driven by EBITDA growth (65%), modest multiple expansion (35%), investments (£271m), realisations (£244m), available finance, including cash (£210m), and commitments (£929m). ...
- Shonil Chande
LIBERUM: Alternatives Daily: OCI | DGI9 | GSF | SEC | SSIT
Oakley Capital Investments - Note: Delivering leading NAV growthDigital 9 Infrastructure - Solid FY22 results and more capital appreciation potential than the share price suggestsGore Street Energy Storage - 16% annual NAV TR for CY 22Strategic Equity Capital - Avoiding commodity-related sectors and banks is increasingly paying offSeraphim Space Investment Trust
- Liberum Research Team
- Liberum Research Team
SFR SEVERFIELD
NEX NATIONAL EXPRESS GROUP PLC
AHT ASHTEAD GROUP PLC
RTN RESTAURANT GROUP PLC
KIE KIER GROUP PLC
FAN VOLUTION GROUP
OCI OAKLEY CAPITAL INVESTMENTS
PAGE PAGEGROUP PLC
TOWN TOWN CENTRE SECURITIES PLC
CTEC CONVATEC GROUP PLC
HMSO HAMMERSON PLC
1B3N THUNGELA RESOURCES LTD
DOM DOMINGUEZ & COMPANIA
- Ciaran Donnelly
- Shonil Chande
LIBERUM: Oakley Capital Investments* - Delivering leading NAV growth
EBITDA growth was the principal driver behind OCI’s 24% NAV total return in FY 2022, contributing 65% of the uplift to portfolio value. The 35% contribution from multiple expansion predominantly reflected five completed exits, achieved at a c.70% average premium to book value and there is potential for attractive realisations in 2023. The key driver of NAV growth will continue to be EBITDA growth and this is a portfolio characterised by 70% of look-through revenues being recurring or subscriptio...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: March 2023
Feature article: Higher interest rates overshadow IIC/REIF prospects We focus on the nine quoted infrastructure investment companies (IICs) and on the 22 renewable energy infrastructure funds (REIFs), most of which saw their share prices fall during 2022, while the FTSE 100 rose by just 0.9%. In our ‘Quoted UK Infrastructure and Renewable Energy – Prospects for 2023’ publication, we have addressed the three key issues of recent months – higher inflation, extremely volatile power prices and risin...
FEV FIDELITY EUROPEAN VALUES PLC
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FSV FIDELITY SPECIAL VALUES PLC
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
AVO ADVANCED ONCOTHERAPY
RECI REAL ESTATE CREDIT INVESTMENTS
PIN PANTHEON INTERNATIONAL
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
OCI OAKLEY CAPITAL INVESTMENTS
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: February 2023
Feature article: Asset manager valuations Asset managers had a poor 2022: the S&P Composite 1500 Asset Management Index was down 22% and, according to the Investment Company Institute (ICI), worldwide mutual funds fell by 20%, from $76tr to $60tr. When bond and equity markets fall, the results are unlikely to be pretty: with revenues trending down and multiples contracting, there is a double whammy to contend with. So how do valuations shape up now, after a bullish start to the new year?
FEV FIDELITY EUROPEAN VALUES PLC
SCE SURFACE TRANSFORMS PLC
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FSV FIDELITY SPECIAL VALUES PLC
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
AVO ADVANCED ONCOTHERAPY
CLIG CITY OF LONDON INVESTMENT GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
PIN PANTHEON INTERNATIONAL
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
OCI OAKLEY CAPITAL INVESTMENTS
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
OCL OAKLEY CAPITAL
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.